About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Leukemia Drug That Kills Cancerous T-cells Without Increasing Risk of Infections

by Thilaka Ravi on January 26, 2012 at 11:48 AM
Font : A-A+

Leukemia Drug That Kills Cancerous T-cells Without Increasing Risk of Infections

A new study reports that low-dose Campath (alemtuzumab) not only treats patients with Leukemic cutaneous T-cell lymphoma (L-CTCL) but does so without increasing their risk of infections.

Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues have reported the new study. The study was electronically published on January 18, 2012 in Science Translational Medicine.

Advertisement

Leukemic cutaneous T-cell lymphoma is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years.

Campath was previously believed to kill all lymphocytes (T-cells and B-cells) in the body and render patients susceptible to infections. However, Clark and Kupper found that Campath only kills T-cells that enter the bloodstream, but it spares a newly discovered population of T-cells that live long-term in the tissues.
Advertisement

"We noticed that our patients were not getting infections, and we looked in the skin. We saw healthy T-cells remaining there despite the fact that there were no T-cells in the blood," said Clark. "We used to believe that most T-cells responsible for protecting against infection were in the bloodstream. But we now realize that highly protective T-cells also inhabit tissues such as the skin, lungs and gastrointestinal tract. It is these tissue resident T-cells that are critical in protecting us from infection on a day-to-day basis."

By showing that Campath kills circulating T-cells, including the cancerous T-cells, but spares tissue resident T-cells, Clark and Kupper have shown that Campath effectively treats L-CTCL while sparing normal immunity. Their findings are also the first demonstration in human beings that tissue resident T-cells provide frontline immune protection of the skin.

"We're very grateful to our patients for entrusting us with their care and for teaching us important lessons about the immune system." said Clark.

In a companion piece, Mark Davis, PhD, Stanford University School of Medicine, called the work a "translational tour de force."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Leukemia Ganglion Cysts - Ganglion Wrist Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Signature Drug Toxicity Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia 

Most Popular on Medindia

Drug Interaction Checker Pregnancy Confirmation Calculator How to Reduce School Bag Weight - Simple Tips Blood Donation - Recipients Find a Hospital The Essence of Yoga Color Blindness Calculator Daily Calorie Requirements Post-Nasal Drip Sinopril (2mg) (Lacidipine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Leukemia Drug That Kills Cancerous T-cells Without Increasing Risk of Infections Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests